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A movement for increased personal autonomy and individual empowerment has seeped into all aspects of
this country's social, political, and economic life. The extent of this movement's inuence is clearly visible
in the conuence of perhaps surprising bedfellows: the politics of the Food and Drug Administration and
a 1951 amendment to the 1938 Food, Drug, and Cosmetic Act, the establishment of contraception use as
a fundamental privacy right in constitutional law, and the increasing power of feminists and reproductive
rights advocates on the democratic process.1 What is responsible for this phenomenon? The latent, but
nonetheless real, controversy over the potential switch of oral contraceptives from prescription only drugs to
drugs available over-the-counter. The aborted initiative to produce such a switch demonstrates that the line
separating individualism from paternalism in the realm of scientic and medical technology is not as bright
as one would think.
Statutory Authority and Legislative History for Prescription to Over-the -Counter Switches
Prior to 1951, and arguably even after 1951, the classication of a drug as prescription or non-prescription
has been rife with uncertainty. The 1938 Federal Food, Drug and Cosmetic Act (the FD&C Act) failed to
include criteria for categorizing a drug as prescription or over-the-counter.2 In response to this omission, FDA
created the concept of federal mandatory prescription status through regulations promulgated in 1938 which
1It is arguable that women's rights and reproductive rights advocates have suered a major set back following the Casey
decision in 1992. See infra Note 101
2Wion, Ann H. Rx to OTC Switch. The Process and Procedures. 19 Drug Info. J. 119 (1985).
1were later amended in 1944.3 Yet until Congress codied these regulations in the 1951 Durham-Humphrey
Amendments to the FD&C Act, dierent manufacturers made dierent choices about whether to market the
same drug as prescription or over-the-counter.4 Motivated by a desire to eliminate this confusion, Congress
included section 503(b)(1) to the FD&C Act when it enacted the Durham-Humphrey Amendments.5 Section
503(b)(1) denes a prescription drug as:
A drug intended for use by man which-
(A) is a habit-forming drug to which section 502(d) applies; or
(B) because of its toxicity or other potentiality for harmful eect or the method of its use,
or the collateral method necessary to its use, is not safe for use except under the supervision of
a practitioner licensed by law to administer such drug; or
(C) is limited by an approved application under section 505 to use under the professional
supervision of a practitioner licensed by law to administer such drug.
Thus, under the statute, a drug must be classied as prescription only if it falls under one of three categories:
(1) habit-forming, (2) not safe for use except under medical supervision because of the drug's toxicity,
potentially harmful eects, or method of use, or (3) limited to prescription status under new drug applications
(NDAs). Since the rst category is limited to 17 specied habit-forming chemicals, or their derivatives, listed
in section 502(d) and since the third category refers to those new drugs which are limited to prescription
status when FDA approves an NDA for drugs falling within the second category, it is the second category
which eectively controls future determinations of drugs as either prescription or over-the-counter.6 Thus, a
potential prescription to over-the-counter switch for oral contraceptives must be rst scrutinized under the
3Hutt, Peter Barton. A Legal Framework for Future Decisions on Transferring Drugs From Prescription to Nonprescription
Status. 37 Food Drug Cosm. L.J. 427 (1982). 427, 428.
4See supra Note 2 at 119.
5See supra note 2 at 119.
6See supra note 3 at 433
2second component of section 503(b)(1).
But what did Congress intend by promulgating the criteria of the second component of section 503(b)(1) and
did Congress envision that drugs such as oral contraceptives would potentially be available over-the-counter?
Since the birth control pill was introduced in 1960, nine years after the passage of section 503(b)(1), the
question of oral contraceptives specically never arose in the amendment's legislative history. Interestingly
enough, however, there was committee testimony regarding human hormones.7 The then FDA Federal
Security Agency Associate Commissioner, George P. Larrick, oered the following testimony regarding potent
drugs:
When the medicines are administered by skilled physicians they cure many ailments. Most of
these drugs, however, are quite potent and capable of doing harm when misused. ... Female sex
hormones, called estrogens, are very useful in the hands of skilled physicians, but in a case under
the Food and Drug Act in California recently, where the drugs were sold without prescription,
eminent medical authorities testied that improper use is capable of stimulating the growth of
incipient cancer; it may impair fertility and cause hemorrhage from the uterus.8
The Associate Commissioner's testimony demonstrates what one congressman articulated as the goal of the
amendment: \...to protect the public in the use of potent medicines which should be sold on prescription...."9
In passing the 1951 amendment, Congress was indeed motivated by the desire to protect public health. But
Congress also recognized that the prescription/over-the-counter status of a drug may change on the basis
711 Legislative History of the Food, Drug & Cosmetic Act 26, (1979) 26, 114
Hearings before the Comm. on Interstate and Foreign Commerce H.Rep. Sess. 1, 82d. Cong. (1951), Statement of George
P. Larrick
8Id at 115
911 Legislative History of the Food, Drug and Cosmetic Act 26 (1979), 26, 324
H.R. Debate, 82d Cong. 1st Sess. (1951)
3of new information.10 As Congressman Durham explained during committee hearings regarding the amend-
ment, any prescription drug may be administratively changed to over-the-counter when its prescription
status is no longer necessary to protect the public health.11Congressional intent was to prevent dispensation
of \harmful drugs" without the supervision of medical professionals, not to prevent self-medication which
utilized relatively safe drugs such as aspirin or \Mothersill's seasick pills."12
Regarding determination of a drug's prescription or over-the-counter status under section 503(b)(1), Congress
intended extensive inquiry to occur.13 Although recognizing that many drugs were not \toxic" or \poi-
sonous," Congress still deemed the potential of these drugs to have an ill eect upon a human being and
their potential to threaten the public health as relevant factors inuencing determination of the drugs'
prescription/non-prescription status.14 15 Thus, although Congress was weary of vesting excessive power in
a government agency and in the agency's commissioner,16 the combination of (1) a broad range of permissible
inquiry accompanying determination of a drug's prescription/non-prescription status, and (2) the less than
mathematical requirements of section 503(b)(1), has created a process in which a drug's status rests largely
on the judgment of FDA.17
FDA Consideration of a Prescription-Over-the-Counter Switch for Oral Contraceptives
Although generally a conservative agency, FDA initiative since the 1980s to change drugs from prescription
10See supra Note 3 at 433
11See supra Note 7 at 38
Statement of Hon. Carl T. Durham, A Representative in Congress from North Carolina
12See supra Note 9 at 351
13See supra Note 3 at 433
14See supra Note 9 at 338
15See supra Note 3 at 433
16See supra Note 8 at 317-318, 326, 329, 333, 337
17The Impact of the Rx-to-OTC Switch Process-Present and Future. 19 Drug Info. J. 85 (1985) 85, 201
4to over-the-counter suggests, for many, a new FDA policy toward over-the-counter status.18 FDA seems
more willing to acknowledge the ability of laypersons to safely and eectively utilize drugs which heretofore
have been limited to prescription status.19 Congruent with this more recent policy, FDA on January 21,
1993 announced in the Federal Register an open committee discussion of the Fertility and Maternal Health
Drugs Advisory Committee (a committee which reviews and evaluates data on the safety and eectiveness
of marketed and investigation human drugs for use in the practice of obstetrics and gynecology) to be held
on February 4 and 5, 1993, to discuss issues related to providing oral contraceptives without prescription.20
The issues scheduled for discussion at the Feb. 4-5 session were to include whether labeling can provide
adequate instruction on the use of oral contraceptives, whether an over-the-counter Pill would place women
at a higher risk of contracting sexually transmitted diseases, and whether over-the-counter availability would
aect the contraceptives' ecacy.21 On January 28, 1993, one week after the posted Federal Register notice
of the committee review, FDA canceled the session.22 The over-the- counter oral contraceptives advisory
committee review was never rescheduled.
FDA's abrupt cancellation of the committee review was allegedly ordered by top FDA ocials and sparked
public speculation as to the reasons for the agency's retreat.23 An FDA spokesman said Commissioner David
Kessler's oce gave the order to cancel the meeting while staers explore a broader agenda and consult with
outside groups about their concerns.24 The press reported that an outpouring of discontent from medical
18Kaplan, Alan H. Over-the-Counter and Prescription Drugs: The Legal Distinction under Federal Law. 37 Food Drug
Cosm.L.J. 441 (1982) 441, 445
19Id.
2058 FR 5400, 5401
21F-D-C Reports-"The Pink Sheet," Feb. 1, 1993
22Id.
23Talks Canceled on Making \Pill" Nonprescription. The Wall Street Journal, January 28, 1993 at B1
24Oral Contraceptives' Move to OTC Hits Major Obstacle. Washington Drug Letter. February 1, 1993, at 5
5and family planning groups led FDA to cancel the advisory committee meeting.25 Answering allegations of
FDA's backing away from a controversy, FDA deputy commissioner for external aairs responded that the
meeting was canceled after FDA ocials decided that the agenda was not broad enough and that the agency
had not consulted with a wide enough range of groups.26
Given the cancellation of the oral contraceptives review, what motivated the scheduled meeting of the
advisory committee in the rst instance? Under \switch-regulation," rst promulgated by FDA in 1956 and
later codied in 21 CFR 310.200, any interested party may petition FDA to exempt a drug that is restricted to
prescription use under the terms of its NDA from its prescription use limitations.27 The Commissioner may
also initiate review of a drug, which may result in over-the-counter status for the drug if FDA determines that
prescription status is no longer necessary to protect the public health.28 Although the Fertility and Maternal
Health Drugs Advisory Committee was not to review any specic company's application at its Feb. 4-5
meeting,29 helping to organize the scheduled meeting was R.W. Johnson Pharmaceutical Research Institute,
the research arm of Ortho Pharmaceutical Corp., producer of the top-selling oral contraceptive brand, Ortho-
Novum.30Apparently, FDA had approached Ortho Pharmaceutical to help organize the meeting.31
Estimates predicted that if sold without a prescription, Johnson and Johnson's birth control pill sales could
double to $500 million.32 Pill sales of other rms producing oral contraceptives, such as American Home,
Bristol-Myers Squib, Monsanto and Warner-Laambert, would also increase; according to outside analysts, a
25Id.
26Supra see Note 23
27Supra see Note 2 at 120-121
28Id. at 121
29F-D-C Reports- \The Pink Sheet." January 25, 1993
30Birth Control Pills May Not Require a Prescription. Washington Post Health. January 19, 1993
31FDA: OTC Birth Control Issue Needs Broad-Based Input. Dickonson's FDA. February 15, 1993 at 8
32Supra see Note 23
6prescription to over-the-counter switch would double the oral contraceptive market to close to $1.6 billion.33
Responding to the cancellation of the advisory committee's meeting, Ortho stated that any discussion of
switching oral contraceptives to over-the-counter status should be made in the best interests of women's
health and take into account all viewpoints.34
History and Development of \the Pill"
In 1950, the Planned Parenthood Federation of America invited an American biologist, Dr. Gregory Pincus,
to develop an ideal contraceptive.35 Planned Parenthood contributed $2,100 to the project and another
$20,000-$30,000 was raised from government and private sources before the research actually began.36 A pill
was developed containing estrogen and progestin, synthetic hormones similar to those produced naturally
in a woman's body, which worked by suppressing the release of eggs from a woman's ovaries.37After clinical
trials on 6,000 women in Puerto Rico and Haiti, the rst commercially produced birth control pill, Envoid-10,
was marketed in the United States.38 The rst oral contraceptives contained 100 mcg to 175 mcg of estrogen
and up to 10 mg of progestin, higher levels than in today's pills, and they were 99 percent eective when
used properly.39
The pill was available prior to 1960, but not as a drug marketed for contraception. Searle initially asked
33Supra see Note 24
34Supra see Note 21
35Snider, Sharon. The Pill: 30 Years of Safety Concerns. FDA Consumer Magazine. Dec. 1990
36Id.
37Id.
38Id.
39Id.
7for FDA approval of a drug for treating menstrual disorders only.40 Searle knew of the drug's contraceptive
eects, but conducted additional testing before applying for permission to market the pill as a contraceptive.41
Thus, FDA rst licensed oral contraceptives for treatment of solely menstrual disorders and required a
warning on the package which stated that women taking the drug would not ovulate.42 Not surprisingly, in
1959 many women suddenly developed \menstrual disorders" which required treatment with the pill.43
Acceptance of the pill among American women occurred quickly. Within two years of its introduction as an
oral contraceptive, approximately 1.2 million women were taking the pill, 5 million within ve years, and
by 1973, about 10 million.44 In the early 1980s, use of the pill dropped to 8.4 million following reports of
possible harmful side eects.45 With the introduction of a low-dose pill on the market, use once again rose
to approximately 10.7 million in 1990.46 With 80 percent of women born after 1945 having used the pill at
some point, it is the most popular method of non-surgical contraception.47
Although oral contraceptives were well received and are still widely used today, concern over side eects
plagued, and continue to surround, the pill's use. Because of the millions of healthy women worldwide who
have used oral contraceptives since their introduction, short-term and long-term use of these drugs is a
public health issue of maximum proportions.48 Not surprisingly, oral contraceptives have been scrupulously
monitored and studied over the last 36 years. According to FDA, more studies have been done on the pill
to look for side eects than have been done on any other medicine in history.49
In 1965, galvanized by reports of blood clotting in several women taking the pill, FDA awarded a research
40Tribe, Lawrence H. Abortion. The Clash of Absolutes. New York: W. W. Norton & Company; 1992, at 218
41Id.
42Id.
43Id.
44Supra see Note 35
45Id.
46Id.
47Supra see Note 40
48Grimes, David A. The Safety of Oral Contraceptives: Epidemiologic Insights From the First 30 Years. 166 Am. J. Obstet.
Gynecol. 1950 (1992)
49Supra see Note 35
8grant to investigate exactly how widespread the problem was.50 At the same time, the agency established
the Advisory Committee on Obstetrics and Gynecology, FDA's rst advisory committee, to review the drugs
and to investigate their eect on blood clotting.51 In 1966, the advisory committee reported that it found
no scientic data to prove the pill unsafe at the time.52 The committee cautioned, however, that the pill was
not in use long enough at the time of the review to draw valid conclusions about any potential carcinogenic
eects.53 A World Health Organization scientic group, which conducted independent studies, conrmed
the advisory committee ndings.54
Concern over the pill's alleged and real side eects, however, continued to brew. Following British studies
in 1968 which found an increased incidence of blood clots among pill users, FDA added information about
the results of those studies to the product labeling for oral contraceptives.55 A year later the labeling was
revised to include the results of U.S. studies which conrmed the earlier British studies.56 In 1969, the
results of ongoing research revealed that risks of blood clots, heart attack, and stroke were directly related
to the level of estrogen in dierent versions of the pill.57 In 1970, FDA issued a bulletin to doctors about
the danger of blood clots and advised prescribing the lowest eective dose of estrogen possible (the 1969
research results indicated that the same level of contraceptive eectiveness could be attained utilizing only
50 mcg of estrogen).58
FDA also once again revised the product labeling to include the \lowest eective dose" and for the rst
time, required that information for patients about the drug's risks be included in every package of oral
contraceptives.59
50Id.
51Id.
52Id.
53Id.
54Id.
55Id.
56Id.
57Id.
58Id.
59Id.
9By the mid-1970s, most women were taking oral contraceptives with estrogen levels of 50 mcg or less.60
The amount of progestin in the drugs had also decreased to between 2.5 and.15 mg.61 In 1982, a new
version of the pill, the \biphasic" pill was introduced, to be followed in 1984 by three \triphasic" pills.
These \multiphasic" pills are low-dose oral contraceptives in which the ratio of progestin to estrogen changes
during the 21 day cycle the pill is taken.62 In 1988, urged by FDA, the drug companies still manufacturing
high-dose estrogen pills voluntarily withdrew from the market all remaining contraceptives containing over
50 mcg of estrogen.63 Most pills prescribed today contain 30 to 35 mcg of estrogen and.5 to 1 mg progestin
(in 1973-1974, FDA approved several low-dose pills containing as little as 20 mcg).64 Oral contraceptives
today pose fewer risks than childbirth for women under age 35.65
Safety Issues and Compliance with Section 503(b)(1)
Traditional safety concerns may no longer justify restricting oral contraceptives to prescription status under
section 503(b)(1). There is at least enough scientic evidence to warrant a review of the drug's current
prescription status - a review not unlike the one originally scheduled by the FDA in 1993, but then canceled.
Most versions of the oral contraceptive pill today have one-third or less estrogen and one-tenth or less
progestin as the oral contraceptive pills of the 1960s.66 Most of the known side eects of the pill today are
60Id.
61Id.
62Id.
63Id.
64Id.
65Trussell, James. Should Oral Contraceptives Be Made Available Without Prescription? 83 Am. J. Public Health 1094
(1983) 1094, 1097
66Buring, Julie E. Low-Dose Oral Contraceptives and Stroke. 335 New England Journal of Medicine53, July 4, 1996 at 53-54
10not medically serious.67 They include possible nausea, breakthrough bleeding, mood changes, weight gain,
breast tenderness, and eye dryness.68 These side eects usually subside within the rst three months of
use.69 Since the amount of estrogen in oral contraceptives has been thought to be chiey responsible for
increased risk of venous thromboembolism, myocardial infarction, and both ischemic and hemorrhagic stroke
(blood clots, heart attacks, and strokes), the low-dose drugs considerably reduce these risks.70
As reported by the New England Journal of Medicine, oral contraceptives, when used by healthy women
of childbearing age do not increase the risk of stroke.71 The majority of studies have found no association
between breast cancer and oral contraceptive use, although several recent reports have suggest that this
cancer is diagnosed more frequently in young women who have used oral contraceptives.72 Given the latest
reports, the risk of increased breast cancer needs to be further explored. Earlier studies linking high-dose oral
contraceptives and cardiovascular disease are no longer relevant to the low-dose drugs currently.73 Recent
studies on low-dose contraceptives have not suggested a link between oral contraceptive use and myocardial
infarction or stroke.74
In addition to considerable evidence indicating the safety of low-dose contraceptives, sophisticated epidemi-
ological studies have revealed the benets of oral contraceptive use. Accompanying the benet of eective
67See supra Note 35
68Id.
69Id.
70Id.
71See supra Note 66
72Coker, Harlap, Fortney. Oral contraceptives and reproductive cancers: weighing the risk and benets. Fam Plann. Perspect.
1993;25:17-21
73See supra Note 65 at 1094-1095
74Id.
11contraception, oral contraceptives protect against the development of ovarian and endometrial cancers, pelvic
inammatory disease, and ectopic pregnancy.75 The drugs are also commonly used to prevent heavy and
irregular menstrual periods.76 Oral contraceptives protect against the development of iron deciency anemia,
primary dysmenorrhea, functional ovarian cysts, and benign breast disease.77 Prevention of osteoporosis,
toxic shock syndrome, and rheumatoid arthritis has also been linked to the use of oral contraceptives.78
Although lower estrogen levels in today's oral contraceptives translate to lower toxicity levels in the drug,
and thus demonstrate less reason to keep oral contraceptives prescription under section 503(b)(1) because of
their toxicity, some safety issues remain unsettled and may be enough in themselves to generate opposition
to the drug's possible switch to over-the-counter status. Contributing to the opposition is concern over use
of the pill by women in high risk groups. Although the studies indicate the pill's relative safeness for healthy,
non-smoking women, the risk of serious illness and death increases for certain groups.79 Women who smoke,
especially those over 35, have signicantly increased risk of heart attack and stroke, increasing with age.80
Women who are obese or have underlying health problems have an increased risk of experiencing serious side
eects.81 Women who have a history of blood clots, heart attack, stroke, liver disease, or cancer of the breast
or sex organs are too high risk use oral contraceptives.82 Thus, the possibility of harmful eects befalling
women in high risk groups who use the pill may necessitate maintaining oral contraceptives as prescription
drugs under section 503(b)(1)(B).
Proponents of a switch, however, argue that keeping oral contraceptives as prescription drugs does not
75See supra Note 48 at 1954
76Id.
77Id.
78See supra Note 65 at 1095
79See supra Note 66
80Id.
81Id.
82Id.
12substantially decrease the likelihood that high risk individuals will use the pill any more so than if oral
contraceptives were available over-the-counter. Switch supporters oer as evidence a study where women
screened themselves for contraindications to oral contraceptives as accurately as clinicians.83 Carefully
designed package labeling, according to proponents, can provide enough information for women to make
an intelligent decision regarding the use of the drug.84 Women can identify contraindications in their own
medical histories and they are capable of conducting breast self-examinations and of obtaining their own
blood pressure reading (at a supermarket for example) prior to using oral contraceptives without medical
supervision.85 Yet, although possible, the chances of women actually following the entire screening procedure
are lower than the probability of its complete execution by a physician. Contrary to one study's results,
reliance on self-screening undoubtedly poses a greater health risk than screening procedures performed by
physicians.
The pill's method of use is another factor to be considered when determining whether oral contraceptives
should remain prescription under section 503(b)(1). Oral contraceptives must be taken daily on a 21-day
or 28-day cycle, with a possibility of dierent pills to be taken on dierent days in the cycle, depending on
the version of the drug used. It is not, at least to the novice user, a necessarily simple procedure. Concern
over the potential switch of the pill's prescription status includes the fear that without medical consultation,
imperfect use of oral contraceptives will increase, thus resulting in the decrease of the drug's ecacy.86
83See supra Note 65
84Id.
85Id.
86Id.
13The ecacy of oral contraceptives does depend on the extent and type of imperfect use.87 Imperfect use
includes missing pills, failing to use backup contraception if pills are missed, taking antibiotics or anticonvul-
sants while on the pill, and disregarding any vomiting or severe diarrhea which occurs.88 Evidence suggests
that many oral contraceptive users miss pills even though they visit a physician to obtain a prescription and
that pill users often ignore cautions on package labeling which warn against particular drug interactions.89
Consequently, proponents of a switch argue that the possibility of pill use non-compliance should not be an
obstacle to the drug's over-the-counter availability since this non-compliance is a phenomenon even under
the drug's current prescription only status.90 Switch proponents concede that imperfect use of oral con-
traceptives will increase without clinical consultations, but with more user-friendly package labeling, the
increase of non-compliance would not be great and certainly would not be enough to outweigh the benets
of making oral contraceptives available over-the-counter.91 The balancing of risks versus benets for an oral
contraception switch is dicult and it is what makes the proposition of such an event so controversial.
Protecting the Public Health
Uncertainty remains over the eects of the pill's lower toxicity levels, the feasibility of women self-screening
to avoid known harmful eects, and the probability of non-compliance with the drug's method of use. Yet
it is true that every drugs carries an element of risk. Enough evidence exists, demonstrating the relative
87Id.
88Id.
89Id.
90Id.
91Id.
14safety of low-dose contraceptives, to justify an exemption for oral contraceptives from section 503(b)(1)'s
literal denition of a prescription drug. Such a decision is within FDA's power and discretion, but it is
complicated by considerations reaching beyond facial compliance (subject to statutory interpretation) with
section 503(b)(1). As articulated by a former FDA General Counsel, drugs such as oral contraceptives
generate sucient public concern for reasons other than toxicity, as to make determination over the drugs'
prescription/nonprescription status dicult.92
FDA's mandate is to protect the public health. This was also Congress's intention when amending section
503(b)(1). Yet the means to accomplishing this awesome task are not always clear and they often dia-
metrically oppose one another. How does an agency recognize an individual's ability to self-medicate, and
ease access to medicinal drugs, while protecting the same individual from the harmful eects of the drug's
potency, or from even him or herself? These questions have divided the medical community and women's
rights advocates within their own ranks, and they are a recurring theme in the debate over a switch to
over-the-counter oral contraceptives.
Women's Health and Autonomy
For many women's rights and family planning advocates, switching the status of oral contraceptives to over-
the-counter is a political issue which signies the increase of women's autonomy. Full and independent access
to oral contraceptives liberates women to make their own decisions regarding when, or if, to have children.
92Hutt, Peter B. Drugs for Self-Medication in the Future: Their Source and the Social, Political, and Regulatory Climate.
19 Drug Info. J. 1995 (1985), 195, 196
15Health and safety issues notwithstanding, contraception has come a long way from its unlawful practice
under the 1873 Comstock Act.
The Comstock Act criminalized the import, mail, or transport in interstate commerce any literature about
birth control or any device designed to prevent conception or cause abortion.93 In the 1936 case, United
States v. One Package, the Supreme Court slightly loosened the vice of the Comstock Act by allowing
products (diaphragms), which may be used by competent physicians to promote the well being of their
patients, to ow in interstate commerce.94 Women, as opposed to physicians, were evidently not permitted
to promote their own well-being. Shadows of the Comstock Act lingered on until in 1965, ve years after oral
contraceptives were rst marketed, Griswold v. Connecticut, the famous contraceptives case, marked the
modern era's recognition of a fundamental privacy right to plan pregnancy.95 96 The trend toward greater
access to contraceptives continued with Eisnenstadt v. Baird97 in 1972 and Carey v. Population Services
Int'l in 1977.98
While access to contraceptives liberalized, women's rights and reproductive rights advocates enjoyed tremen-
dous success with the hallmark Roe v. Wade decision in 1973.99 The Court in Roe v. Wade held that women
93See supra Note 72
94Id.
95Id.
96Griswald v. Connecticut, 381 U.S. 479 (1965). The Court in Griswald protected the right of married persons to use
contraceptives by striking down a statute which made criminal the use of contraceptives and the aiding or counseling of others
in their use.
97Eisenstadt v. Baird, 405 U.S. 438 (1972). The Court broadened the contraceptive aspect of privacy to reach unmarried
couples.
98Carey v. Population Services Int'l, 431 U.S. 678 (1977). The Court in Carey struck down a New York statute which
prohibited anyone but a licensed pharmacist from distributing contraceptives to persons over 16 and which entirely prohibited
the sale or distribution to minors under the age of 16, except by prescription.
99Roe v. Wade, 410 U.S. 113 (1973)
16have a Fourteenth Amendment fundamental right to privacy and that therefore the legislature has only a
limited right to regulate, and may not completely prohibit, abortions.100 This, for many women, meant the
power to control one's own body - it meant autonomy. Yet in 1992, this autonomy was drastically curtailed
by the Court in Planned Parenthood of Southeastern Pennsylvania v. Casey.101 Casey overturned abortion's
status as a fundamental right.102 As a result, states may now restrict abortions as long as a woman's right to
choose is not unduly burdened. With greater restriction on abortion, a woman's ability to plan and control
pregnancy is vastly impaired.
The loosening of restrictions on contraceptive use in the modern era, partnered with the recent setback
for women's right to choose abortion, should have sent family- planning and reproductive rights advocates
clamoring for a switch from prescription to over-the-counter status for oral contraceptives. Such a switch
would increase availability of the drug to women by reducing obstacles, such as the time and cost of doctor's
visits and the general stigma of prescription drug use, and thus giving women more control over their own
bodies and reducing the number of unwanted pregnancies. Over-the-counter status for oral contraceptives
would allow women to regain some of the momentum toward autonomy they experienced following Griswald,
but lost after Casey.
Yet surprisingly, many representatives of women's groups oppose the oral contraceptive switch to over-the-
counter status and these representatives expressed their dissatisfaction with the proposal to FDA following
100Id.
101Planned Parenthood of Southeastern Pennsylvania v. Casey, 505 U.S. 833 (1992)
102Id.
17the scheduled Feb. 4-5 review meeting.103They oppose the switch on a number of counts, Medicaid cov-
erage being one of them. Medicaid will not cover nonprescription birth control pills.104 Consequently,
without reimbursement, over-the-counter oral contraceptives, for many low-income women, will become cost
prohibitive, may actually reduce the pill's use among these women.105 Lower income women's access to
contraception is a valid concern, however, it may be possible for physicians to still write a prescription for
the drugs, perhaps thus enabling women to be reimbursed for the expense.
Another reason some family-planning advocates oppose a switch in prescription status of oral contraceptives
is the potential decrease in consultations with physicians. Switch opponents argue that women who have
not consulted clinicians may be scared o by unexpected side-eects and may stop using the pill, creating
more unwanted pregnancies.106 It is possible, however, that women experiencing these side eects would
then visit physicians rather just stop oral contraceptive use. Opponents also fear that a switch would
result in deterioration of women's overall health because of more infrequent visits with physicians. The
medical director of Planned Parenthood Federation was quoted as saying, \[w]e've been using the pill as
bait to get women in for other medical tests."107 Yet the \bait" theory angers supporters of the switch,
eliciting responses such as, \[t]hat's like saying we're going to put condoms on prescription so we can test
men for cancer of the testes."108 It is indeed possible that with more women using over-the-counter oral
contraceptives, these women will be more conscious of their physical health and may actually be more likely
to consult with physicians than if they were not using oral contraceptives at all.
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18There is also another, somewhat dubious, yet critical, reason for Planned Parenthood's opposition to a switch
in prescription status. Many family planning clinics raise a signicant portion of their revenue from selling
oral contraceptives.109 The clinics buy the contraceptives from drug companies at a discount and then sell
the pills at a higher rate.110 If drug companies face a more competitive over-the-counter market, they may no
longer provide low-cost pills to clinics.111 Family-planning clinics will have diculty replacing the millions
of dollars of lost revenue necessary to subsidize their operations.112 Unfortunately, this is a greater issue
than just \the bottom line;" there is need for concern. Family-planning clinics are a tremendous resource for
counseling, medical, and educational services. If the clinics' ability to provide these services are impaired,
it is unlikely that government or private enterprise can replace their crucial role in maintaining the public
health. This is actually one of the most compelling policy reasons in favor of maintaining oral contraceptives'
current prescription only status.
Sexually Transmitted Diseases
Sexually transmitted diseases are indeed to be feared and protected against. Many opponents of an oral
contraceptives switch to over-the-counter status, oer the possibility of a rise in sexually transmitted diseases
as a reason to maintain the drug's current prescription status. Japan's eort to contain the diseases, by com-
pletely banning oral contraceptives, is often used as ammunition by opponents in debates against advocates
of the switch to over-the-counter status. But preventing the change of prescription status for birth control
pills is not the answer to the sexually transmitted diseases problem, education is.113 Concern over sexually
transmitted diseases applies not only to the use of oral contraceptives, but also to all hormonal contracep-
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19tives, intrauterine devices, spermicides, cervical caps, sponges, and diaphragms.114 In fact, as part of ongoing
education eorts, FDA in 1993 notied the manufacturers of intrauterine devices, implantable and injectable
contraceptives, and natural membrane condoms, as well as oral contraceptives, that labeling accompanying
their products must state that they do not provide protection from sexually transmitted diseases, including
AIDS.115 FDA informed manufacturers that the information was to be displayed prominently in clear lan-
guage for the consumer.116 These are the eorts which protect against sexually transmitted diseases, not
limiting the availability of a method of contraception.
Conclusion
The choice between maintaining oral contraceptives at their current prescription drug status or switching
the drugs to over-the-counter status, like so many other decisions in Food and Drug Law, has as much to
do with science, as it does with politics and economics. If the second component of section 503(b)(1)(B) of
the FD&C Act gave more formulaic guidance for determining which drugs were exempt from its reach, then
determination of drugs' prescription/nonprescription status would be simpler. Yet if this were indeed the
case, then the amended statute would not leave room to analyze the total social cost versus the total social
benet that a drug's availability over-the-counter would inspire. Protection of the public health, Congress's
ultimate purpose for the FD&C Act and its 1951 amendments, would be dicult to achieve.
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20Although the pill's lower toxicity level translates to less risk of harmful side eects than was the case when
it was rst introduced in the 1960s, the pill is still not without its risks, especially for women with high risk
group characteristics. Maintaining the pill's prescription status ensures a pre-use screening by a clinician
and decreases the probability of oral contraceptive use by high risk consumers. This is a compelling reason
to maintain the status quo, but is restriction of a contraceptive, especially with the establishment of contra-
ception as a fundamental privacy right, the least costly solution to maintaining the public health? If we have
any faith in the increasing intelligence of consumers and in information and education eorts such as package
labeling and patient package inserts, perhaps increase in high risk women actually using oral contraceptives
will not be as great as opponents of a switch to over-the-counter status predict.
With somewhat varying scientic data and less than bright-line statutory denition of a prescription drug,
it is not surprising that FDA, in all of its discretion to make the prescription/nonprescription drug de-
termination, would consider broader social and economic implications of an oral contraceptives switch to
over-the-counter availability. Notwithstanding debate surrounding consumer's ability to use the drugs safely
without physician consultations, concern regarding both the viability of family-planning clinics and the
availability of the oral contraceptives to lower income women following a switch to over-the-counter status is
probably the greatest impediment to such a switch. Regardless of one's political and social mores, the ser-
vices which family-planning clinics contribute to the maintenance of the public health are undeniably crucial.
Unless resources are found, or raised, in order to continue the operation of these clinics, or unless alternative
comparable services are provided by some other means (perhaps manufacturers of oral contraceptives will
make a charitable contribution), the combination of the loss of these services, with the decreased availability
of the drug for lower income women (who arguably need the drug most), and the possible increase of harmful
eects befalling high risk consumers, will make a switch to over-the-counter status for prescription drugs
politically dicult, if not impossible.
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